inflammatory system have been proposed and recent research links these inflammatory processes with cognitive function, suggesting that the presence of inflammation is associated with poorer cognitive performance (Ribeiro-Santos et al., 2014, Cabrera et al., 2016. The study of the influence of gender on the possible association between inflammatory biomarkers and cognitive performance may favor the implementation of personalized treatments. The aim of the study is to investigate the association between inflammatory biomarkers and gender-based cognition in a sample of first psychotic episode (FEP). A total of 92 patients with a FEP, 62 men and 30 women, recruited in five clinical centers were included. A neurocognitive assessment was performed and the expression of pro and anti-inflammatory mediators in peripheral blood mononuclear cells (PBMC) and plasma was measured. Methods: In the neurocognitive evaluation the domains of attention, verbal and working memory and executive function were included. Other and clinical variables included the assessment of psychotic and affective symptoms, age, sex, educational level and socio-economic level. The expression of the proinflammatory mediators (NFκB, iNOS, COX-2, PGE2, NO-2 and TBARS) and anti-inflammatory (15d-PGJ2, PPARγ and IκBα) of the main intracellular inflammatory pathway was measured in PBMC and plasma. Results: A correlation was made between inflammatory biomarkers and neurocognitive performance according to gender, and significant associations were selected to perform a subsequent hierarchical regression analysis. In the final model, only the expression of COX2 was associated with better performance in executive function in males (B = 0.504, p = <0.001) and the expression of NO2 to worse performance in working memory in women (B = -0.911; p = 0.010), after controlling the confounding factors. Men and women did not differ in any of the confusing variables. Discussion: The expression of certain pro / anti-inflammatory components could have a differential effect according to the gender of patients with FEP. The expression of COX2 could be beneficial in the case of males, explaining part of the variability in executive function. On the contrary, the expression of NO2 could have a detrimental effect on working memory in women. The establishment of biomarkers linked to gender-based cognition could be useful for monitoring the course of cognitive decline and could guide treatment programs, providing tools to select a personalized approach. 
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F13. TOWARDS MOLECULAR INSIGHTS INTO PSYCHIATRIC DISORDERS USING AFFINITY PROTEOMICS

Uppsala University
Background: Numerous studies have shown a correlation between high autoantibody titers and subsequent autoimmune disease in patients with psychiatric disorders compared to healthy individuals. In this study we used a targeted affinity proteomics approach to investigate these autoantibody repertoires. We therefore obtained serum samples from patients diagnosed with various psychiatric disorders and compared these with samples of healthy volunteers. Additionally we used our approach to identify autoantibodies in post mortem brain tissue from patients diagnosed with schizophrenia. Methods: In this study we utilized a well characterized cohort of patients with psychiatric disorder to study the autoantibody repertoire. From this sample set we analysed more than 600 serum in a first discovery approach. Based on the in-house screening and previous external published studies of autoantibodies within psychiatry we selected a set of 231 protein fragments from the Human Protein Atlas with a length of roughly 80 amino acids.
With this selected panel we screened additional 130 post mortem brain tissue samples. Autoantibody profiling was performed using suspension bead array technology and IgG reactivity was measured in patients and controls.
Results: Our findings could indicate altered immune response in patients with psychiatric disorders compared to healthy controls. In our study we identified potential predictive autoimmune signatures. Those were presented with higher IgG reactivity in patients compared to healthy control samples. Discussion: With our approach we were able to profile autoantibody repertoires in patients with psychiatric disorders. Additionally, we were able to use our approach to profile brain tissue using a multiplexed affinity proteomics approach. By further validating these putative autoimmunity targets, we could gain insights into the autoantigens associated to chronical mental illnesses. Background: Abnormal mismatch negativity (MMN), thought to be a putative marker of glutamatergic function, has been reported in non-Asian, first episode schizophrenia and clinical high-risk for psychosis (CHR) individuals as indicative of impairments in pre-attentive processes. However, reports of abnormal MMN in Asian populations are sparse, as well as its relationships to glutamate and γ-aminobutyric acid (GABA) levels in medial prefrontal cortex. The present longitudinal study explored MMN differences between CHR subjects who will and who will not remit, and its relationships with prefrontal glutamate and GABA levels. Methods: All subjects participated in the ShangHai At-Risk for Psychosis (SHARP) program. CHR subjects met the criteria defined by the Chinese version of the Structural Interview for Prodromal Syndromes (SIPS). From the SHARP sample, 76 CHR subjects (41 male, age 18.63 ± 5.02 years) and 53 HC (31 male, age 17.72 ± 3.18 years) completed both MMN test and proton magnetic resonance spectroscopy (1H MRS) scans using a MEGA-PRESS sequence at their initial visit. CHR subjects were divided into remitted (37) and non-remitted (34) individuals based on their clinical symptoms and functional scores at a one-year follow up. Duration MMN amplitude was measured at electrodes F1/2, Fz, FC1/2, FCz, C1/2 and Cz. Concentrations of glutamate+glutamine (Glx) and GABA in the medial prefrontal cortex (mPFC) were quantified using the LCModel software (version 6.3-0I). Repeated measures analysis of variance (ANOVA) with group (remitted CHR, non-remitted CHR and HC) as the between-group factor and electrodes (Fz, FCz and Cz) as the within-group factor were performed for the midline sites, and the ANOVA using F1/2, FC1/2 and C1/C2 with laterality (left and right hemisphere) as an additional within-group factor was performed for the lateral sites. Correlations of the dMMN amplitude (averaged over the 9 electrodes) and Glx and GABA concentrations were assessed by Pearson correlation tests for each group. Results: There was a significant main effect of group (F(2,121)=3.14, p<0.05) for the midline fronto-central dMMN amplitude. Post-hoc tests showed that non-remitted CHR subjects had lower baseline dMMN amplitude (-4.75 ± 0.37μv) than HC (-5.92 ± 0.30μv, p<0.05), whereas dMMN in remitted CHR (-5.22 ± 0.36μv, p=0.41 ) was comparable to dMMN in HC. The main effect of group was marginally significant at lateral sites (F(2,121)=2.83, p=0.06). DMMN amplitude in non-remitted CHR (-4.67 ± 0.37μv) tended to be lower than those in HC (-5.76 ± 0.29μv, p<0.1), while remitted CHR had dMMN amplitude (-5.11 ± 0.35μv, p=0 .47) comparable to HC. There was no significant main effect of laterality or interaction of group × laterality. In non-remitted CHR subjects, dMMN amplitude was significantly correlated with Glx level (r=-0.47, p<0.01) and with GABA level (r=-0.38, p<0.05) in the mPFC. However, the correlation of dMMN amplitude with Glx or GABA levels was not significant among either HC or remitted CHR. Discussion: In line with previous studies, reduced dMMN amplitude distinguished between remitted and non-remitted CHR subjects, with remitted CHR not different from HCs. Our finding further supports the idea that reduced dMMN amplitude could be a candidate biomarker for predicting outcome in CHR. More importantly, we linked the reduced dMMN amplitude in non-remitted CHR to their Glx and GABA levels in mPFC, the region identified as one of dMMN sources (responsible for attention switching) thus supporting the idea that NMDA-mediated disruptions may play a key role in predicting psychosis and functional outcome. Background: Environmental risk factors that operate at maternal, foetal and post-natal levels, causing immune activation are known risk factors for schizophrenia. How this risk is transduced is unknown but one plausible disease mechanism may be through immune activation perturbing central nervous system growth factor systems, such as the epidermal growth factor (EGF) system critical to neuronal differentiation, maturation and plasticity, altering neurodevelopment. These interactions between EGF and immune systems may involve specific critical brain regions and not others.
F14. REDUCED DURATION MISMATCH NEGATIVITY ASSOCIATED WITH DECREASED GLUTAMATE+GLUTAMINE LEVEL IN SUBJECTS AT CLINICAL HIGH-RISK FOR PSYCHOSIS
F15. DIFFERENTIAL EXPRESSION PATTERNS OF EPIDERMAL GROWTH FACTOR (EGF) AND IMMUNE SYSTEM MARKERS IN
Methods:
The expression of candidate genes from EGF and immune systems and related signalling pathways, including ligands, receptors and intermediary molecules, were examined in post-mortem dorsolateral prefrontal (DLPFC) (n=114 genes) and orbitofrontal cortical (OFC) (n=105 genes) tissues, from schizophrenia and mood disorder patients and healthy controls (n=68), using the Fluidigm Biomark qRT-PCR platform. Data were analysed by ANOVA or corresponding non-parametric test (KruskalWallis) in GraphPad Prism 6/7 statistical software and p values were adjusted for multiple testing (Benjamini-Hochberg).
Results: In DLPFC, 68 genes were significantly differently expressed between diagnostic groups. In comparison to healthy controls, 60 genes were differentially expressed in schizophrenia and 14 in the mood disorder group. Collectively these differentially expressed genes belonged predominantly to ERBB signalling and associated MAPK, PI3K and MTOR pathways and with immune pathways involving toll like receptor (TLR), TNF, nuclear factor kappa B (NFB), JAK-STAT, and complement signalling. Although there was some overlap the expression profiles in schizophrenia and mood disorder differed considerably. There were genes (n=15) with significantly lowered expression in both patient groups compared to controls which belonged predominantly to immune pathways such as TNF and TLR. However, 36 genes were differentially expressed between schizophrenia and mood disorder, all of them having lower expression in schizophrenia, predominantly representing pathways PI3K/MTOR, MAPK, TLR and TNF signalling via NFKB. Gene expression in EGF system signalling via MAPK and PI3K pathways, and interleukin signalling via JAK-STAT were significantly lower in schizophrenia than in mood disorder and healthy controls. ErbB4 was the only gene significantly elevated in a patient group (mood disorder) compared to the controls. In comparison to DLPFC, only five genes out of the 105 examined were differentially expressed between the diagnostic groups in OFC, which belonged to NFB, TLR, JAK-STAT and growth factor signalling pathways. In comparison to healthy controls all were differentially expressed in schizophrenia and three genes in the mood disorder group. The expression of most genes was decreased in the patient groups compared to control subjects in both brain regions. Discussion: We conclude that there is a prominent regional difference in the expression of EGF and immune system markers, identifying the DLPFC as a region of high activity for the interaction between these two systems relative to the OFC. In this region, the differing profiles of gene expression between schizophrenia and mood disorder involved EGF signalling pathways including PI3K/MTOR and MAPK along with immune pathways such as TNF, TLR and JAK-STAT signalling, possibly reflecting variant pathological processes involving immune and EGF system signalling between these sets of disorders.
F16. GLUTAMATE AND GABA LEVELS IN ANTIPSYCHOTIC-NAÏVE SCHIZOPHRENIA PATIENTS ARE ASSOCIATED WITH TREATMENT OUTCOME AFTER 1.5 AND 6 MONTHS
